Hemodialysis | Cardiovascular Protective Effect of Spironolactone in Hemodialysis
Hemodialysis research study
What is the primary objective of this study?
The purpose of the present study is to determine if spironolactone is safe and effective in
the treatment of cardiovascular complications in hemodialysis patients.
Who is eligible to participate?
chronic hemodialysys (> 3 months) anuria (diuresis <200 mL/day) -
Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or
agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Phase: Phase 4
Study sponsors, principal investigator, and references
Principal Investigator: Luis F Michea, MD PhD
Lead Sponsor: Universidad Los Andes, Chile
Michea L, Vukusich A, González M, Zehnder C, Marusic ET. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004 Oct;66(4):1647-53.